Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Guilford Pharmaceuticals Inc.

Division of Eisai Co. Ltd.

Latest From Guilford Pharmaceuticals Inc.

Betting on Safety: The IoM Report's Impact on Wall Street

The Institute of Medicine is recommending big changes in how FDA deals with drug safety issues. Is it possible that will be good news on Wall Street? Drug safety expert and managing director of investment company Symphony Capital, Alastair Wood, weighs in.

BioPharmaceutical Business Strategies

Genentech and Inotek Pair Up in PARP Inhibition

For the first time, oncology drug development is being grounded in the ability to take advantage of a readily identifiable genetic flaw in certain types of tumor cells. Research reveals that tumor cells containing the BRCA1 or BRCA2 gene variants are exquisitely sensitive to attack by inhibitors of poly (ADP-ribose) polymerase, or PARP. Now comes a deal between PARP specialist Inotek Pharmaceuticals and Genentech.


FDA Safe at Home: Looks Inside for Top Safety Official

After a tumultuous, two-year hiatus, FDA finally has a permanent director for the Office of Drug Safety. Gerald Dal Pan, MD, succeeded Victor Raczkowski, ending a drawn out serach for what is increasingly becoming a politically sensitive middle management job within FDA.

Leadership Regulation

Deal Statistics Quarterly, Q3 2005

In this issue, we present another installment of our quarterly review of dealmaking for July-September 2005. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Eisai Co. Ltd.
  • Senior Management
  • Dean J Mitchell, CEO
    William F Spengler, EVP, CFO
    Barbara S Slusher, PhD, SVP, Research
    Russell Wesdyk, VP, Bus. Dev.
    Michael Kelly, VP, Sales & Mktg.
  • Contact Info
  • Guilford Pharmaceuticals Inc.
    Phone: (410) 631-6300
    6611 Tributary St.
    Baltimore, MD 21224